Retinopathy of prematurity: applicability and compliance of guidelines in Hong Kong

Luk, Abbie S W; Yip, Wilson W K; Lok, Julie Y. C.; Lau, Hung; Young, Alvin L.

doi:10.1136/bjophthalmol-2016-308900

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies showed that many hospitals in Hong Kong follow the UK screening criteria for ROP screening [7][8][9]26,27 ; consistent with our findings, the reported incidences of ROP and type 1 ROP in Hong Kong were 16% to 28% 7-9 and 3.4% to 3.8%, [7][8][9] respectively. In the present study, type 1 ROP mainly developed in extremely preterm infants with a median GA of 26 weeks and 0.5 days (IQR=2 weeks & 2.5 days), suggesting that low GA was an important predictor of type 1 ROP in our population.…”

Section: Discussionsupporting

confidence: 91%

“…5,6 In Hong Kong, many hospitals use the UK screening criteria to guide ROP detection. [7][8][9] Although the UK screening criteria are appropriate for ROP detection in many countries, [10][11][12] they are not universally appropriate. [13][14][15][16][17][18] In India 14,15,19 and China, 17,18 some infants with GA and BW above the UK screening thresholds also developed severe ROP requiring treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of United Kingdom and United States screening criteria for detecting retinopathy of prematurity in Hong Kong

Yip

Lok

et al. 2023

Hong Kong Med J

View full text Add to dashboard Cite

Introduction:We examined whether the United Kingdom (UK) or the United States (US) screening criteria are more appropriate for retinopathy of prematurity (ROP) screening in Hong Kong, in terms of sensitivity for detecting type 1 ROP and the number of infants requiring screening. Methods:In this retrospective cohort study, we reviewed the medical records of all infants who underwent ROP screening from 2009 to 2018 at a tertiary hospital in Hong Kong. During this period, all infants born at gestational age (GA) ≤31 weeks and 6 days or birth weight (BW) <1501 g (ie, the UK screening criteria) underwent ROP screening. We determined the number of infants requiring screening and the number of type 1 ROP cases that would have been missed if the US screening criteria (GA ≤30 weeks & 0 days or BW ≤1500 g) had been used.Results: Overall, 796 infants were screened using the UK screening criteria. If the US screening criteria had been used, the number of infants requiring screening would have decreased by 21.1%; all type 1 ROP cases would have been detected (38/38, 100% sensitivity). Of the 168 infants who would not have been screened using the US screening criteria,

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Comparison of United Kingdom and United States screening criteria for detecting retinopathy of prematurity in Hong Kong

Yip

Lok

et al. 2023

Hong Kong Med J

View full text Add to dashboard Cite

show abstract

“…In our clinic, we found the incidence of ROP to be 16.2% during a three-year follow-up, in infants with a birth weight of less than 32 weeks and/or birth weight of less than 1500 g, and infants with a birth weight of over 32 weeks and/or birth weight of over 1500 g, who required cardiorespiratory support and determined to be at risk of ROP by the clinician. Our ROP frequency was found to be lower when compared to the results reported from countries that applied similar screening protocols in the literature [6,[10][11][12] .…”

Section: Discussioncontrasting

confidence: 56%

Risk Factors, Screening Results and Intravitreal Ranibizumab Treatment of Retinopathy of Prematurity

Arcagök¹

2021

Haydarpasa Numune Med J

View full text Add to dashboard Cite

Introduction:The aim is to evaluate the incidence of retinopathy of prematurity within three years in premature babies followed up in our clinic, to determine the risk factors that play a role in the development of retinopathy, to evaluate intravitreal ranibizumab treatment and its results. Methods: Babies with a birth weight of ≤32 weeks and/or a birth weight of ≤1500 grams and babies determined to be at risk by the clinician were examined for the development of retinopathy. Risk factors including week of birth, birth weight, mode of delivery, gender, APGAR scores, need for mechanical ventilation, ≥40% oxygen therapy, duration of oxygen therapy, surfactant therapy, acidosis, hypoxia, sepsis, erythrocyte transfusion, intraventricular hemorrhage, apnea and anemia were compared between cases who developed or did not develop retinopathy of prematurity. Results: The mean birth week of the babies was 30.1±0.24 weeks (23-36 weeks), and the mean birth weight was 1362.3±378.6 grams (450-2020 grams). Retinopathy of prematurity at different stages was detected in 21 (16.2%) of 130 patients. Eight (6.1%) of all patients screened for retinopathy of prematurity required treatment. Intravitreal ranibizumab was administered to seven patients (5.3%) with Stage III retinopathy, and both ranibizumab and laser therapy were applied to one patient with Stage IV retinopathy. Week of birth and low birth weight (p<0.001), duration of oxygen therapy (p<0.001), receiving surfactant treatment (p=0.002), sepsis (p<0.001), blood transfusion (p<0.001), intraventricular haemorrhage (p=0.019), apnea (p<0.001), anemia (p<0.001), hypoxia (p<0.001), acidosis (p<0.001) and low APGAR score (p<0.001) were found to significantly decrease the risk of developing retinopathy of prematurity. Discussion and Conclusion: The development of retinopathy of prematurity can be reduced by appropriate management of risk factors that increase retinopathy of prematurity, such as low birth week and weight, high concentration and long-term oxygen use. Although there is no clear recommendation for the treatment of retinopathy of prematurity, it is thought that intravitreal ranibizumab treatment may be a good option in selected cases.

show abstract

“…Recent reports suggest between 9–40% of screened infants will develop ROP, and an even smaller number will require treatment. 78,135,136,230,239,255 ROP examinations can cause significant morbidity in neonates, including decreased oxygen saturation levels, increased heart rate, and increased apnea events. Also, unnecessary examinations may increase the medical costs for ROP screening.…”

Section: Retinopathy Of Prematuritymentioning

confidence: 99%

Retinopathy of prematurity: a review of risk factors and their clinical significance

Kim

Port

Swan

et al. 2018

Survey of Ophthalmology

400

337

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a retinal vasoproliferative disease that affects premature infants. Despite improvements in neonatal care and management guidelines, ROP remains a leading cause of childhood blindness worldwide. Current screening guidelines are primarily based on two risk factors: birth weight and gestational age; however, many investigators have suggested other risk factors, including maternal factors, prenatal and perinatal factors, demographics, medical interventions, comorbidities of prematurity, nutrition, and genetic factors. We review the existing literature addressing various possible ROP risk factors. Although there have been contradictory reports, and the risk may vary between different populations, understanding ROP risk factors is essential to develop predictive models, to gain insights into pathophysiology of retinal vascular diseases and diseases of prematurity, and to determine future directions in management of and research in ROP.

show abstract

Retinopathy of prematurity: applicability and compliance of guidelines in Hong Kong

Abstract: Current ROP screening using the UK guidelines (2008) is applicable, effective and safe to our predominantly Asian population in Hong Kong, with a low rate of delayed screening.

Cited by 7 publications

References 24 publications

Comparison of United Kingdom and United States screening criteria for detecting retinopathy of prematurity in Hong Kong

Comparison of United Kingdom and United States screening criteria for detecting retinopathy of prematurity in Hong Kong

Risk Factors, Screening Results and Intravitreal Ranibizumab Treatment of Retinopathy of Prematurity

Retinopathy of prematurity: a review of risk factors and their clinical significance

Contact Info

Product

Resources

About